Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H34O6 |
| Molecular Weight | 430.5339 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@@]2(O1)C(=O)CO
InChI
InChIKey=VOVIALXJUBGFJZ-VXKMTNQYSA-N
InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21+,22+,23-,24-,25+/m0/s1
| Molecular Formula | C25H34O6 |
| Molecular Weight | 430.5339 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 9 / 9 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Pneumomediastinum and pneumopericardium: unusual and rare complications of asthma in a 4 years old girl. | 2001-07-14 |
|
| Fluticasone propionate and budesonide do not influence bone metabolism in the long term treatment of asthma. | 2001-07-14 |
|
| Corticosteroids in the treatment of pediatric allergic rhinitis. | 2001-07 |
|
| Assessing the effect of intranasal steroids on growth. | 2001-07 |
|
| Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. | 2001-07 |
|
| Pharmacokinetics of intranasal corticosteroids. | 2001-07 |
|
| Proinflammatory cytokines and eosinophil cationic protein on glandular secretion from human nasal mucosa: regulation by corticosteroids. | 2001-07 |
|
| The linear relationship between changes in childhood growth velocity and topical glucocorticoid dose. | 2001-06-27 |
|
| On-demand relief treatment for asthma. | 2001-06-09 |
|
| On-demand relief treatment for asthma. | 2001-06-09 |
|
| Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada. | 2001-06 |
|
| Comparison of montelukast versus budesonide in the treatment of exercise-induced bronchoconstriction. | 2001-06 |
|
| Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids. | 2001-06 |
|
| Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma. | 2001-06 |
|
| Comparison of once daily fluticasone propionate aqueous nasal spray with once daily budesonide reservoir powder device in patients with perennial rhinitis. | 2001-06 |
|
| Adding formoterol to budesonide in moderate asthma--health economic results from the FACET study. | 2001-06 |
|
| A successful switch from prednisone to budesonide for neuropsychiatric adverse effects in a patient with ileal Crohn's disease. | 2001-06 |
|
| Benign intracranial hypertension associated with budesonide treatment in children with Crohn's disease. | 2001-06 |
|
| Interleukin-13 upregulates eotaxin expression in airway epithelial cells by a STAT6-dependent mechanism. | 2001-06 |
|
| Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity. | 2001-06 |
|
| The problem of dose-response and therapeutic ratio of inhaled steroids. | 2001-06 |
|
| Meconium induces expression of inducible NO synthase and activation of NF-kappaB in rat alveolar macrophages. | 2001-06 |
|
| Relevance and reproducibility of patch-test reactions to corticosteroids. | 2001-06 |
|
| [Precise direction or flexible self-control. How strictly must the asthma patient adhere to medical advice?]. | 2001-05-10 |
|
| Effect of budesonide and nedocromil sodium on IL-6 and IL-8 release from human nasal mucosa and polyp epithelial cells. | 2001-05 |
|
| Ex-vivo product performance of Diskus and Turbuhaler inhalers using inhalation profiles from patients with severe chronic obstructive pulmonary disease. | 2001-05 |
|
| A comparison of the efficacy and safety of a half dose of fluticasone propionate with beclamethasone dipropionate and budesonide in childhood asthma. | 2001-05 |
|
| Patch test results with tixocortol pivalate and budesonide in Germany and Austria. | 2001-05 |
|
| Approach to corticosteroid-dependent and corticosteroid-refractory Crohn's disease. | 2001-05 |
|
| Conventional treatment of Crohn's disease: objectives and outcomes. | 2001-05 |
|
| Comparison of the cost-effectiveness of budesonide and sodium cromoglycate in the management of childhood asthma in everyday clinical practice. | 2001-05 |
|
| Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: impact of budesonide treatment and withdrawal. | 2001-05 |
|
| Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. | 2001-05 |
|
| [Powder inhaler with integrated motor. The anti-asthmatic drug stays fresh]. | 2001-04-19 |
|
| [Bronchial asthma. Combination therapy becomes simpler]. | 2001-04-05 |
|
| Stability and performance characteristics of a budesonide powder for inhalation with a novel dry powder inhaler device. | 2001-04 |
|
| Therapeutic equivalence of the Sofotec Novolizer to established standard devices in COPD and asthma. | 2001-04 |
|
| Scintigraphic evaluation of lung deposition with a novel inhaler device. | 2001-04 |
|
| A comparison of topical budesonide and oral montelukast in seasonal allergic rhinitis and asthma. | 2001-04 |
|
| Quality of life indices may be predictive of placebo and medication response to treatment for allergic rhinitis. | 2001-04 |
|
| Eosinophilic gastroenteritis treated with non-enteric-coated budesonide tablets. | 2001-04 |
|
| Glucocorticoids and TGF-beta1 synergize in augmenting fibroblast mediated contraction of collagen gels. | 2001-04 |
|
| A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects. | 2001-04 |
|
| The effect of intranasal budesonide spray on mucosal blood flow measured with laser Doppler flowmetry. | 2001-03 |
|
| Inhalation of corticosteroids after hospital care for respiratory syncytial virus infection diminishes development of asthma in infants. | 2001-03 |
|
| Extrafine beclomethasone dipropionate breath-actuated inhaler (400 micrograms/day) versus budesonide dry powder inhaler (800 micrograms/day) in asthma. | 2001-03 |
|
| Inhaled corticosteroids reduce growth. Or do they? | 2001-02 |
|
| Skin reactions to inhaled corticosteroids. | 2001 |
|
| Holding chambers versus nebulisers for inhaled steroids in chronic asthma. | 2001 |
|
| Topical corticosteroids in nasal polyposis. | 2001 |
Sample Use Guides
In vitro biotransformation of the 22R (Dexbudesonide) and 22S epimers of the topical steroid budesonide was studied in the S-9 fraction of human liver, bronchus, skin and colonic mucosa. A marked decay of the initial concentration of unchanged budesonide epimers was noticed after 2 h incubation in cultured human hepatocytes, while only a small decrease was observed after 24 h incubation in cultured human airway smooth muscle cells and BEAS-2B cells. The 22R epimer of budesonide suffered greater in vitro biotransformation than the 22S epimer in human hepatic, bronchial and colonic tissues.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:13:42 GMT 2025
by
admin
on
Mon Mar 31 18:13:42 GMT 2025
|
| Record UNII |
2HI1006KPH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51372-29-3
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
257-161-7
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
100000087782
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
7805
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
SUB01627MIG
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110662
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
DTXSID401017799
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
Dexbudesonide
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
C80814
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
40000
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY | |||
|
2HI1006KPH
Created by
admin on Mon Mar 31 18:13:43 GMT 2025 , Edited by admin on Mon Mar 31 18:13:43 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> AGONIST |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
|
